Business Context and Reporting Period
This Form 8-K filing by Ultragenyx Pharmaceutical Inc. reports a material definitive agreement entered into on February 4, 2015. The filing details a public offering of common stock that closed on February 10, 2015.
Key Financial Metrics
- Shares Issued: 3,000,000 shares of common stock.
- Public Offering Price: $54.00 per share.
- Underwriter Purchase Price: $50.76 per share.
- Estimated Net Proceeds: Approximately $151.8 million (after deducting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 450,000 shares.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the capital raise transaction.
Material Changes
The primary material change is the increase in equity capital and cash liquidity resulting from the sale of 3,000,000 shares. This transaction represents a significant dilution event for existing shareholders and a substantial infusion of cash for the Company.
Outlook, Risks, and Contingencies
Management Commentary: The Company utilized an automatically effective shelf registration statement (Form S-3) to execute the offering. The underwriters include Morgan Stanley & Co. LLC, Cowen and Company, LLC, and Jefferies LLC.
Risks and Contingencies: The Underwriting Agreement includes indemnification provisions where the Company agrees to indemnify the Underwriters against certain liabilities under the Securities Act of 1933 or contribute to payments required by the Underwriters due to such liabilities.
Investor Verification Checklist
- Verify the final closing date and whether the 450,000 share over-allotment option was exercised.
- Confirm the actual net proceeds received versus the estimated $151.8 million.
- Review the Company's subsequent use of proceeds to ensure alignment with stated strategic goals.
- Check for any subsequent filings regarding the indemnification obligations mentioned in the Underwriting Agreement.